NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $350,338 | -24.7% | 587,989 | -27.3% | 0.00% | – |
| Q2 2023 | $465,394 | -68.2% | 809,049 | -61.2% | 0.00% | – |
| Q1 2023 | $1,464,669 | +25319.5% | 2,084,461 | -18.3% | 0.00% | -100.0% |
| Q4 2022 | $5,762 | -99.9% | 2,550,049 | +103.6% | 0.00% | 0.0% |
| Q3 2022 | $4,007,000 | -37.6% | 1,252,372 | -25.8% | 0.00% | 0.0% |
| Q2 2022 | $6,418,000 | -40.5% | 1,688,969 | -15.7% | 0.00% | -33.3% |
| Q1 2022 | $10,795,000 | -48.5% | 2,002,601 | +29.1% | 0.00% | -50.0% |
| Q4 2021 | $20,960,000 | -7.7% | 1,551,168 | +22.6% | 0.01% | -14.3% |
| Q3 2021 | $22,720,000 | -17.7% | 1,265,013 | -21.4% | 0.01% | -22.2% |
| Q2 2021 | $27,623,000 | +45.1% | 1,609,632 | +69.1% | 0.01% | +50.0% |
| Q1 2021 | $19,036,000 | +42.7% | 951,931 | +21.4% | 0.01% | +20.0% |
| Q4 2020 | $13,336,000 | +1.6% | 783,969 | -0.9% | 0.01% | -16.7% |
| Q3 2020 | $13,121,000 | -12.2% | 790,742 | +22.5% | 0.01% | -14.3% |
| Q2 2020 | $14,943,000 | +78.0% | 645,565 | +37.3% | 0.01% | +75.0% |
| Q1 2020 | $8,394,000 | +67.1% | 470,233 | +101.7% | 0.00% | +100.0% |
| Q4 2019 | $5,023,000 | +87.6% | 233,157 | +58.4% | 0.00% | +100.0% |
| Q3 2019 | $2,678,000 | -90.9% | 147,192 | -82.3% | 0.00% | -90.9% |
| Q2 2019 | $29,569,000 | +35.9% | 831,319 | +28.4% | 0.01% | +22.2% |
| Q1 2019 | $21,753,000 | +61.9% | 647,578 | +58.5% | 0.01% | +50.0% |
| Q4 2018 | $13,433,000 | -1.8% | 408,526 | +82.0% | 0.01% | +20.0% |
| Q3 2018 | $13,683,000 | +30.2% | 224,471 | +4.3% | 0.01% | +25.0% |
| Q2 2018 | $10,511,000 | -52.4% | 215,275 | +3.5% | 0.00% | -55.6% |
| Q1 2018 | $22,104,000 | +167.3% | 208,021 | +50.2% | 0.01% | +200.0% |
| Q4 2017 | $8,269,000 | +2196.9% | 138,464 | +803.8% | 0.00% | – |
| Q1 2017 | $360,000 | +91.5% | 15,321 | 0.0% | 0.00% | – |
| Q4 2016 | $188,000 | -96.5% | 15,321 | -95.1% | 0.00% | -100.0% |
| Q3 2016 | $5,422,000 | -15.8% | 315,619 | -30.2% | 0.00% | -25.0% |
| Q2 2016 | $6,438,000 | -14.4% | 452,446 | -17.3% | 0.00% | -20.0% |
| Q1 2016 | $7,521,000 | -53.6% | 547,013 | -43.1% | 0.01% | -50.0% |
| Q4 2015 | $16,204,000 | +299.8% | 961,613 | +160.0% | 0.01% | +233.3% |
| Q3 2015 | $4,053,000 | +19200.0% | 369,863 | +27216.3% | 0.00% | – |
| Q4 2014 | $21,000 | +31.2% | 1,354 | 0.0% | 0.00% | – |
| Q3 2014 | $16,000 | -20.0% | 1,354 | -12.9% | 0.00% | – |
| Q2 2014 | $20,000 | +5.3% | 1,554 | 0.0% | 0.00% | – |
| Q1 2014 | $19,000 | -13.6% | 1,554 | -20.5% | 0.00% | – |
| Q4 2013 | $22,000 | -12.0% | 1,954 | -17.0% | 0.00% | – |
| Q3 2013 | $25,000 | -7.4% | 2,354 | 0.0% | 0.00% | – |
| Q2 2013 | $27,000 | – | 2,354 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |